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t
sObjectives: A current trend in total hip replacement (THR) is the use of
minimally invasive surgery. Little is known, however, about the impact
of minimally invasive THR on resource use and length of stay. This
study analyzed the effect of minimally invasive surgery on hospital
costs and length of stay in German hospitals compared with conven-
tional treatment in THR. Methods: We used patient-level administra-
ive hospital data from three German hospitals participating in the
ational cost data study.We conducted a propensity scorematching to
ccount for baseline differences between minimally invasively and
onventionally treated patients. Subsequently, we estimated the treat-
ent effect on costs and length of stay by conducting group compari-
ons, via paired t tests andWilcoxon signed-rank tests, and regression
nalyses. Results: The three hospitals provided data from 2886 THR
atients. The propensity score matching led to 812 matched pairs.
are M
ty fo
ttp://dx.doi.org/10.1016/j.jval.2012.06.008ength of stay was significantly higher for conventionally treated pa-
ients (11.49 days vs. 10.90 days; P  0.05), but total costs did not differ
ignificantly (€6018 vs. €5986; P  0.67). We found a difference in the
allocation of costs, with significantly higher implant costs for mini-
mally invasively treated patients (€1514 vs. €1375; P 0.001) in contrast
to significantly higher staff and overhead costs for conventionally
treated patients. Conclusions: Minimally invasive surgery was com-
pared with conventional THR and was found to be associated with a
reduced length of stay. Total hospital costs, however, did not differ
between the two treatment groups, because of higher implant costs for
minimally invasively treated patients.
Keywords: economics, hip arthroplasty, hospital, minimally invasive.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Total hip replacement (THR) has been described as “the operation
of the century” [1]. It is a high-volume surgical procedure [2] that is
considered to be successful for the treatment of diseases such as
coxarthrosis [3]. With approximately 200,000 procedures each
year, hip replacement is one of themost frequent kinds of surgery
in German hospitals [4]. Because of demographic change and the
increasing use of this procedure in older age groups, the demand
for hip replacement is expected to increase further [5–8]. In recent
years, there is a trend of using minimally invasive (MI) surgery
approaches in THR [1]. MI surgery approaches were developed on
the basis of conventional approaches and are supposed to reduce
pain, postoperative blood loss, rehabilitation time, and length of
hospital stay [9]. Similar to conventional procedures in THR, a va-
riety of different MI approaches exist [10] but a coherent definition
of MI THR is lacking [11]. In some articles, an MI THR is defined by
the length of incision (10 cm) [12–15], whereas in other articles, it
is defined by the minimization of tissue and muscle dissection
[16]. Although a number of studies have been published that com-
pare MI THR with conventional THR, evidence about its relative
merits is still limited [10,17–19]. In particular, the direct costs of an
MI procedure in THR for hospitals have hardly been studied [20]
* Address correspondence to: Julia Röttger, Department of Health C
35, D-10623 Berlin, Germany.
E-mail: Julia.Roettger@tu-berlin.de.
098-3015 – see front matter Copyright © 2012, International Socie
ublished by Elsevier Inc.despite the fact that, given the high number of THR procedures,
even slight changes in direct costs can be expected to be important
for the respective hospitals.
In this study,we assessed the effect ofMI THR surgery on direct
hospital costs and length of stay (LOS) in German hospitals com-
pared with the effect of convention surgery for THR.
Material and Methods
We used patient-level administrative hospital data from German
hospitals participating in the national cost data study conducted
by the Institute for the Hospital Remuneration System. The data
include sociodemographic, medical, and treatment information,
as well as cost data. Hospitals participating in the national cost
data study use a standardized cost accounting approach, reporting
direct hospital costs in 99 cost categories. Treatment information
includes type of treatment, provided by the German procedure
codes (Operationen- und Prozedurenschlüssel [OPS]), and date of
treatment. Medical information is given by International Statistical
Classification of Diseases, 10th Revision, German Modification (ICD-10-
GM) (Version 2008), including principal and secondary diagnoses
recorded during hospital admission, along with conditions ac-
quired or developed during the hospital stay. A distinction be-
anagement, Berlin University of Technology, Strasse des 17. Juni
r Pharmacoeconomics and Outcomes Research (ISPOR).
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1000 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 9 9 – 1 0 0 4tween diagnosis at admission and conditions acquired at the hos-
pital is only partially possible as the administrative data in
Germany do not formally make this differentiation.
From approximately 250 hospitals, 31 that participated in the
national cost data study provided patient-level data from the year
2008.We identified patients with a recorded primary THR by using
the first five digits of the OPS codes 5-820.0x and 5-820.2x. As no
specific OPS code exists for MI THR, we classified patients as MI
treated if the OPS code 5-986 “minimally invasive technique” was
recorded. Patients who had also undergone a revision hip arthro-
plasty, identified by OPS code 5-821.xx, were excluded from the
analysis. Hospitals with either no conventional THR or no MI THR
were excluded, as we aimed to compare MI and conventional
cases from the same hospitals.
We contacted the remaining hospitals and asked 1) whether
they coded MI THR consistently via the OPS code 5-986 and 2)
which treatment patterns were a prerequisite for coding a patient
as MI THR. After consultation with the relevant professional med-
ical association, we included only those hospitals in the sample
that consistently coded MI THR via the OPS code 5-986 given a
surgical approach that minimizes tissue and muscle dissection.
The hospitals kept in the samplewere recontacted andwere asked
to provide data from 2009.
For our outcome variable “total cost”, we summed up all re-
ported costs. To allow further analysis, we grouped the 99 cost
categories into the following 7 categories: staff costs—medical ser-
vice; staff costs—nursing service; staff costs—medical-technical
service; pharmaceutical costs; implant costs; costs for further
medical devices; and overhead costs.
We calculated the LOS as the difference between the date of
admission and the date of discharge. We also divided the LOS into
further categories: preoperative LOS (pre-LOS), the difference be-
tween the date of admission and the date of surgery, and postop-
erative LOS (post-LOS), the difference between the date of surgery
and the date of discharge.
Using observational studies for the analysis of treatment effect
suffers from one drawback in comparison with randomized con-
trolled trials: Individuals who receive treatment (MI surgery) are
likely to differ in various baseline characteristics from those who
do not (conventional surgery). These differences may affect the
outcome, leading to biased estimates of the treatment effect [21].
Nevertheless, using administrative data has some advantages: it
allows for treatment to be examined as it occurs in routine clinical
care [22] and includes relatively large sample sizes [23]. Since in-
dividuals in routine clinical care are not randomly assigned for
treatment,methods adjusting for themissing randomization have
to be applied [24]. To address the treatment-selection bias, we ap-
liedpropensity scorematching [25]. In thepropensity scoremethod,
all covariates that might predict treatment and influence the out-
come are reduced into a single score, which represents the probabil-
ity of treatment assignment conditional on observed background
covariates [26]. Assuming that no other confounders exist, match-
ing on propensity scores mimics a randomized treatment assign-
ment, with matched treated and untreated individuals having the
same probability of being treated.
We estimated the probability of selection for MI surgery (the
propensity scores) by using multivariate logistic regression analy-
sis. In the model we included all potential confounders, that is,
factors that had been reported to be associatedwith both treatment
selectionandoutcome (costs andLOS).We identifiedconfounderson
the basis of a literature search, leading to a total of four confounding
factors for our propensity scoremodel: age [27–31], sex [27,28,30,31],
besity [32–35], and the diagnosis indicating the THR (e.g., coxar-
hrosis or osteonecrosis) [27]. Since according to previous studies
arious factors are associated with LOS and hospital costs and an
xtended LOS has been associated with an increase in resource
se [29,30,36,37], we used the same propensity scores and conse-uently the same matched sample for both variables of interest
total costs and LOS).
In addition,we includeddummyvariables indicating thehospital
f treatment, because this approach has been reported suitable to
ccount for a hierarchical data structure (in our study, patients
reated in hospitals) [38]. To avoid confounding by different years of
the data,we conducted a subgroupmatching.Wefirst calculated the
propensity scores and conducted the matching for each year sepa-
rately. Subsequently, wemerged the 2008 and 2009 data.
The matching was conducted by using a one-to-one caliper
matching with replacement. On the basis of previously published
studies, we chose a caliper width of 0.2 of the SD of the logit of the
propensity score [39] and assessed the matching quality by using
standardized differences [40]. We rated standardized differences
of up to 10% between the covariates as adequately balanced [41].
fter the matching, we excluded all nonmatched cases from the
ample and conducted all further statistical analysis by using the
atched sample.
The effect of the treatment strategy was analyzed in two steps.
n a first step, differences between the two treatment groups in our
utcome variables (costs and LOS), as well as in the respective
ubgroups, were assessed by using paired t test and, as a nonpara-
etric alternative, Wilcoxon signed-rank test.
In a second step, we applied generalized linear models (GLMs)
o estimate the effect of an MI treatment on total costs and LOS.
e used generalized estimating equations to account for the
atched data structure. In the GLMs, we controlled for additional
actors that had been associated with hospital costs and LOS: fur-
her treatment strategies, such as acetabular roof construction;
ype of implant (cementless, cemented, or hybrid) [29,42,43]; type
f admission (emergency or elective) [44]; and comorbidities as-
essed through the Charlson index [37]. We included these factors
nly in the GLMs but not in the propensity score matching either
ecause they were not related to treatment selection or because
hey could not be determined before treatment. In the GLMs with
OS as the dependent variable, we specified a model with a Pois-
on distribution and a log-link. For the dependent variable total
ost, we specified a model with a normal distribution and the nat-
ral log of the costs as the dependent variable.
In the propensity score model and the GLMs, we included all
actors using dummy variables, except for the continuous variable
ge. The value of the dummies was set as 1 if the treatment or the
iagnosis had been reported and as 0 if it had not been reported.We
etrieved all necessary information from the sociodemographic and
edical information included in the administrative electronic pa-
ient files. Obese patients (bodymass index 30 kg/m2) were identi-
ed by using the ICD-10 code E66. To include the diagnosis leading to
he THR,we grouped the cases according to theirmain diagnosis. If a
ase had a primary diagnosis not related to THR, we screened all
econdary diagnoses and grouped according to those. Finally, we
rouped the diagnosis into the five dummy variables: coxarthrosis,
racture, arthritis, osteonecrosis, and others.
In addition, we applied the enhanced ICD-10–based version of
he Charlson index [45,46] to account for comorbidities. Following
his approach, we first calculated a weighted global Charlson in-
ex score by identifying the relevant ICD-10 codes recorded as
econdary diagnoses and by overweighting the 6 most severe
mong the 17 dimensions of comorbidity proposed by Charlson:
he “Hemiplegia/Paraplegia,” “Renal disease,” and “Cancer (any
alignancy)” comorbidities are weighted by a coefficient 2, cases
f “Moderate or severe liver diseases” by a coefficient 3, and “Met-
static solid tumor” and the “AIDS/HIV” cases by a coefficient 6
see Charlson et al. [45] for details). We then used the Charlson
ndex score to group patients into two dummy variables: Charl-
on1 (patients suffering from one single nonsevere comorbidity;
harlson score 1) and Charlson2 (patients suffering from at leastone severe or two nonsevere comorbidities; Charlson score  1).
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1001V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 9 9 – 1 0 0 4In all statistical analysis, a P value of 0.05 was considered
tatistically significant. All statistical analyses were performed
ith SAS 9.2.
Results
The 31 hospitals providing data for our study had an average of 448
beds. Most hospitals were private not-for-profit hospitals (n 19),
followed by public hospitals (n  10) and private for-profit hospi-
tals (n 2). From the 31 hospitals in our data, we had to exclude 28
hospitals because of no THR cases, no MI cases, or inconsistent
coding of MI cases.
The remaining three hospitals provided the additional data
from 2009, leading to a final sample of three hospitals and 2886
cases. Compared with the total sample, the remaining hospitals
had fewer beds on average (mean 300) and they were all private
not-for-profit hospitals.
In the three hospitals, MI THR was defined by reduced tissue
and muscle dissection. The sample characteristics are displayed
in Table 1. A total of 812 (28.14%) patients were treated with MI
urgery. The average age of the patients was 67 years, and 60.33%
ere women. Coxarthrosis was the most frequent diagnosis
90.61%), followed by arthritis (4.23%), osteonecrosis (2.22%), and
ractures (1.56%). It was found that 1.39% of the patients had none
f these diagnoses and was summed up in the group “other diag-
osis.” In the sample, 18.71% of the patients were coded as obese,
8.02% had a Charlson score of 1, and 4.44% had a Charlson score
bove 1. In more than 80% of the cases, cementless prostheses
ere used, followed by hybrid prostheses (15.59%) and cemented
rostheses (2.08%). Acetabular roof reconstruction was found in
.14% of the patients, and osteosynthesis equipment was used in
.62% of the cases.
The average LOSwas 11.85 3.86 days with aminimum LOS of
days and a maximum LOS of 75 days. The average pre-LOS was
.27  2.13 days, and the average post-LOS was 10.66  3.35 days.
The total direct hospital costs ranged from €3,364 to €27,960
with a mean of €6,146  €1,340. The overhead costs were respon-
sible for the largest share of total costs, followed by implant costs,
staff costs (nursing service, medical service, and medical-techni-
Table 1 – Sample characteristics (n = 2886).
Variable Mean (SD)/%
(number of cases)
Patient characteristics
Age 67.12 (11.10)
Sex male 39.67% (1,145)
Obesity 18.71% (540)
Coxarthrosis 90.61% (2,615)
Arthritis 4.23% (122)
Osteonecrosis 2.22% (64)
Fracture 1.56% (45)
Other diagnosis 1.39% (40)
Charlson1 18.02% (520)
Charlson2 4.44% (128)
Emergency 1.91% (55)
Treatment
Minimally invasive 28.14% (812)
Cementless prosthesis 82.33% (2,376)
Cemented prosthesis 2.08% (60)
Hybrid prosthesis 15.59% (450)
Acetabular roof reconstruction 1.14% (33)
Osteosynthesis equipment 0.62% (18)
SD, standard deviation.cal service), costs for medical devices, and pharmaceutical costs.Both logistic regression models (for the years 2008 and 2009)
calculating the propensity scores had a high ability of predicting
treatment type (2008: c-statistic  0.869; 2009: c-statistic  0.852).
Matching on the propensity scores resulted in a total of 812matches;
thus, every MI case could be matched to a conventional case. Dif-
ferences in the unmatched sample indicate that conventionally
treated patients were older, were more likely women, and were
more likely obese. MI treated patients were more likely to have
coxarthrosis as the main diagnosis. After matching the patients
along covariates and cluster variables, the standardized differ-
ences reduced substantially, from between 0.47% and 137.39% in
the unmatched sample to between 0.25% and 6.65% in the
matched sample (see Appendix Table 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2012.06.008). According to
the predefined threshold of 10%, we rated the matched sample as
adequately balanced.
After the matching, the differences between the convention-
ally and the MI treated cases consisted in further treatment strat-
egies and comorbidities. The biggest difference was regarding the
kind of prosthesis, as MI patients were more likely to have a ce-
mentless prosthesis (82.39% vs. 90.39%) while conventional pa-
tients were more likely to receive a hybrid prosthesis (12.07% vs.
7.76%). Conventionally treated patients also experiencedmore se-
vere comorbidities; 11.08% of the patients had a Charlson score of
1 and 7.27% had a Charlson score above 1, compared with 13.18%
and 4.10% of the MI treated patients, respectively.
The results of the group comparisons are shown in Tables
2 and 3. In the matched sample, conventionally treated patients
who were compared with MI treated patients had a significantly
longer LOS (11.49 days vs. 10.90 days) and post-LOS (10.29 days vs.
9.71 days). In the unmatched sample, the difference in LOS be-
tween conventionally and MI treated patients was higher than in
the matched sample (12.22 days vs. 10.90 days).
While we found a slight but nonsignificant difference in the total
cost between MI (€5986) and conventional (€6018) cases in the
matched sample, we found significant differences in the other cost
categories. For conventionally treated patients, significantly higher
costs were reported for overhead costs and all staff cost categories,
that is, medical service, nursing service, and medical-technical ser-
vice.Only the reported implant costswere significantlyhigher for the
MI cases. In the unmatched sample, however, we found a bigger
difference in the total cost betweenMI andconventional cases (€6208
vs. €5986). It has to be considered though that differences in the P
value between thematched and unmatched group comparisons are
also determined by the different sample sizes.
Table 4 displays the allocation of costs for conventional andMI
cases. In both groups, overhead costs account for the highest share
of total costs, with 27% in the conventional surgery group and 26%
in the MI surgery group, followed by implant costs, which account
for 23% and 25%, respectively.
The results from the GLMs (Tables 5 and 6) are consistent with the
prior results fromthegroupcomparisons: anMI treatment significantly
reduced LOS, but therewas no significant effect on total costs.
Discussion
A total of 812 matched pairs resulted from the propensity score
matching. Thus, every MI THR case was matched with a conven-
tional THR control and no MI THR cases had to be excluded.
The results of the group comparisons show thatMI treated THR
patients have a significantly shorter LOS and post-LOS, controlling
for diagnosis, age, sex, obesity, hospital, and year of treatment.We
found no significant difference in the total cost between MI and
conventional cases, but we found differences in the cost catego-
ries, with implant costs as the only cost category significantly
higher for MI treated patients. Differences in implant cost are
partly explained by different implants for conventional and MI
1002 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 9 9 – 1 0 0 4THR but are also because MI patients more frequently were given
the more expensive cementless prostheses [42,43]. Staff costs and
overhead costs were significantly higher in conventionally treated
patients. The allocation of costs shows that overhead as well as
implant costs account for themajority of the total costs. Thus, our
results suggest that despite differences in terms of LOS, the lack of
significant total cost difference between the two treatment groups
Table 2 – Comparison of LOS (in days) of MI and conventio
Variable Mean Median
LOS
Conventional 11.49 11
MI 10.90 10
Pre-LOS
Conventional 1.24 1
MI 1.26 1
Post-LOS
Conventional 10.29 10
MI 9.71 9
LOS unmatched (n  2886)
Conventional 12.22 12
MI 10.90 10
CI, confidence interval; LOS, length of stay; Pre-LOS, preoperative leng
SD, standard deviation.
* Paired t test.
† Wilcoxon signed-rank test.
‡ Unequal variance t test.
Table 3 – Comparison of hospital costs (in €) of MI and con
Variable Mean Median
Total
Conventional 6,018 5,885
MI 5,986 5,851
Staff—Medical service
Conventional 925 832
MI 881 821
Staff—Nursing service
Conventional 925 861
MI 895 820
Staff—Medical-technical service
Conventional 622 555
MI 593 545
Implant
Conventional 1,375 1,206
MI 1,514 1,445
Pharmaceuticals
Conventional 109 104
MI 109 97
Medical devices
Conventional 438 444
MI 426 418
Overhead
Conventional 1,624 1,507
MI 1,568 1,457
Total unmatchted (n  2886)
Conventional 6,208 5,996
MI 5,986 5,851
CI  confidence interval; MI, minimally invasive; SD, standard deviat
* Paired t test.
† Wilcoxon signed-rank test.
‡ Unequal variance t test.is due to the higher implant costs for MI patients. This finding is
consistent with a previous study showing that implant costs are a
major cost driver in THR [36].
The results of the GLMs indicate that the type of treatment (MI
compared with a conventional surgery) in THR has a significant
effect on LOS, withMI patients having a reduced LOS after control-
ling for diagnosis, age, sex, obesity, comorbidities, hospital and
treated patients (n = 1624).
Max SD 95% CI P
46 3.33 11.26–11.72 0.01*
75 4.39 10.60–11.20
33 1.94 1.10–1.37 0.34†
30 2.29 1.10–1.42
24 2.71 10.11–10.48 0.001*
66 3.62 9.46–9.96
47 3.56 12.07–12.37 0.001‡
75 4.39 10.60–11.20
stay; Post-LOS, postoperative length of stay; MI, minimally invasive;
ionally treated patients (n = 1624).
in Max SD 95% CI P
97 25,491 1,521 5,913–6,123 0.67*
26 27,960 1,527 5,881–6,091
53 5,645 369 900–951 0.001†
70 5,406 305 860–902
43 4,248 227 899–951 0.05†
7 6,847 422 866–924
24 2,993 227 607–638 0.001†
01 2,849 197 579–606
10 2,951 483 1,342–1,408 0.001†
18 3,689 514 1,479–1,550
23 836 73 99–118 0.94*
23 3,074 136 104–114
18 2,952 201 424–452 0.19*
06 2,545 180 414–439
36 7,761 510 1,588–1,659 0.05*
24 10,000 550 1,531–1,606
64 25,491 1,255 6,154–6,262 0.001‡
26 27,960 1,527 5,881–6,091nally
Min
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treatment is associated with a decrease in LOS by 4.3%. With an
intercept of 10.81 days, this relates to a change of approximately
0.5 days and thus is very similar to the results from the univari-
ate group comparison. In the GLMs with hospital cost as the de-
pending variable, we could not find an effect of an MI treatment.
Therefore, the results of our analysis suggest that when com-
pared with a conventional approach to THR, an MI approach leads
to a reduced LOS with no differences in total costs. On the one
hand, from a hospital management perspective, considering that
there is no difference in the reimbursement of MI THR and con-
ventional THR, an MI approach in THR is attractive as a possible
way of saving resources through shorter LOS. On the other hand,
theMI approach is associatedwith higher implant costs. Incurring
higher implant costs may lead to pressure to reduce costs in other
cost categories to avoid the higher overall costs for MI THR com-
paredwith conventional THR. Still, with a reduced LOS andno cost
differences, anMI THR approach ismore attractive than a conven-
tional approach fromahospitalmanagement perspective. Overall,
the differences between theMI and the conventional approach are
rather small. Thus, a clear recommendation for or against MI THR
is not possible, especially as we cannot estimate the differences in
medical outcome. Further studies that assess the quality of the
different treatment approaches are needed.
To our knowledge, this is the first study that analyzes the effect
of MI treatment for THR on hospital costs and LOS by using obser-
vational data to ensure a relatively large sample size and esti-
mates from routine operations. If observational data are used to
compare different treatment groups, however, there is a high
Table 4 – Allocation of costs for conventionally and MI
treated patients (n = 1624).
Cost category Conventional Minimally Invasive
Mean (€) % allocation
of costs
Mean (€) % allocation
of costs
Medical service 925 15.38% 881 14.72%
Nursing service 925 15.37% 895 14.95%
Medical-technical
service
622 10.34% 593 9.90%
Pharmaceuticals 109 1.80% 109 1.82%
Implant 1,375 22.85% 1,514 25.29%
Other medical
devices
438 7.28% 426 7.12%
Overhead 1,624 26.98% 1,568 26.20%
Total costs 6,018 100% 5,986 100%
Table 5 – Results from the GLM, dependent variable:
length of stay (n = 1624).
Parameter Estimate SE 95% CI P
Intercept 2.3808 0.0120 2.3572–2.4044 0.0001
Acetabular roof
construction
0.0519 0.0192 0.0894–0.0143 0.01
Osteosynthesis
equipment
0.1410 0.0737 0.0036–0.2855 0.0559
Cementless Ref.
Cemented 0.3439 0.0995 0.1489–0.5390 0.001
Hybrid 0.0450 0.0278 0.0095–0.0996 0.1057
No comorbiditiy Ref.
Charlson1 0.0683 0.0234 0.0224–0.1142 0.01
Charlson2 0.3927 0.0821 0.2319–0.5535 0.0001
Emergency 0.3761 0.0757 0.2277–0.5245 0.0001
MI 0.0442 0.0165 0.0765–0.0120 0.01
CI, confidence interval; GLM, generalized linear model; MI, mini-
mally invasive; Ref., reference category; SE, standard error.chance for wide baseline imbalances, likely due to treatment-se-
lection bias. To account for baseline imbalances, we implemented
a propensity score matching. Because German hospital data do
not make it possible to distinguish between diagnosis at admis-
sion and conditions acquired during the hospital stay, we carefully
chose the diagnoses for inclusion in the propensity scoremodel and
included only those diagnoses that had very likely been recorded
before the hip replacement. As a propensity score matched-pair
sample does not consist of independent subjects, suitable methods
formatched data have to be applied [47].We did this by using paired
t test andWilcoxon signed-rank test for the group comparisons and
GLMswith generalized estimating equations for the regression anal-
ysis [48]. The differences between the matched and the unmatched
group comparisons clearly indicate how the baseline imbalances be-
tweenMIandconventionally treatedpatients influence the results.A
careful consideration of possible baseline imbalances is necessary
when observational data are analyzed to assess the difference be-
tween MI and conventional THR.
Our study suffers from several limitations. Using hospital re-
cords for our analysis, the quality of the data and our results are
highly determined by the coding quality of the participating hos-
pitals. In particular, an inconsistent coding of the treatment strat-
egywould bias the results and possiblyminimize statistical differ-
ences between the two treatment groups. Because hospitals in
Germany do not have a financial incentive for coding an MI tech-
nique of THR because reimbursement for MI and conventional
THR does not differ, we assumed that not all hospitals in Germany
code MI THR regularly and also do not code MI THR if a conven-
tional THRhad been conducted (i.e., there is no “upcoding”: coding
of a more expensive procedure even though the cheaper alterna-
tive is used). To ensure interpretability of our results, we included
only those hospitals that affirmed a consistent coding of MI THR,
resulting in a sample of only three hospitals. Hence, the sample is
not representative of all hospitals in Germany, and the generaliz-
ability of our results is limited. In addition, it is not possible tomake
inferences about causality based on our study. Randomized con-
trolled trials provide much stronger evidence for causality because
the randomization process ensures that the groups are comparable
on observed and unobserved factors. Thus, further studies, espe-
cially randomized controlled trials analyzing the economic impact of
MI surgery in THR, are still needed.
Furthermore, our study suggests that future research based on
observational data needs to carefully distinguish among different
definitions of THR MI surgery because we find that only 3 of 23
hospitals with THR procedures consistently coded MI surgeries by
Table 6 – Results from the GLM, dependent variable: Log
of total costs (n = 1624).
Parameter Estimate SE 95% CI P
Intercept 8.6450 0.0074 8.6304–8.6596 0.0001
Acetabular roof
construction
0.0817 0.0141 0.0541–0.1093 0.0001
Osteosynthesis
equipment
0.2644 0.0454 0.1754–0.3533 0.0001
Cementless Ref.
Cemented 0.2077 0.0659 0.0786–0.3368 0.01
Hybrid 0.0548 0.0156 0.0242–0.0853 0.001
No comorbidity Ref.
Charlson1 0.0074 0.0125 0.0171 to 0.0319 0.55
Charlson2 0.1783 0.0407 0.0984–0.2581 0.0001
Emergency 0.1539 0.0520 0.0521–0.2558 0.01
MI 0.0098 0.0083 0.0064 to 0.0260 0.23
CI, confidence interval; GLM, generalized linear model; MI, mini-
mally invasive; Ref., reference category; SE, standard error.using the OPS code 5-986. In fact, although 77% of the German
c[
[
1004 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 9 9 – 1 0 0 4surgeons report using MI surgery [16], it lacks a clear definition.
Both professional medical associations and policymakers in Ger-
many need to clarify relevant definitions and procedure codes.
Source of financial support: The data collection for this analy-
sis was funded through the Seventh Framework Programme (FP7)
of the European Commission under Grant Agreement Number
223300.
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